Dicerna Pharmaceuticals Inc 's

• DRNA's Stock Performance relative to its Competitors

Arrowhead Pharmaceuticals Inc Share Performance +1.68% Over The Past 5 Days

Arrowhead Pharmaceuticals Inc Profile Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that primarily focuses on developing RNA interference (RNAi) therapeutics to treat a wide range of diseases. Their business model revolves around discovering and optimizing RNAi-based drug candidates, conducting preclinical and clinical studies for regulatory approval, and ultimately licensing or partnering with larger pharmaceutical companies for commercialization. By leveraging RNAi technology, Arrowhead aims to address unmet medical needs and provide innovative treatments for patients. More about Arrowhead Pharmaceuticals Inc 's Market Share

Regulus Therapeutics Inc Share Performance +444.00% This Quarter

Regulus Therapeutics Inc Profile Regulus Therapeutics Inc's business model focuses on developing and commercializing RNA-targeted therapeutics. More about Regulus Therapeutics Inc 's Market Share

Atrium Therapeutics Inc Share Performance -71.82% One Year

Atrium Therapeutics Inc Profile Avidity Biosciences Inc's business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body. More about Atrium Therapeutics Inc 's Market Share

Sagimet Biosciences inc Share Performance +25.17% 30 Days

Sagimet Biosciences inc Profile Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community. More about Sagimet Biosciences inc 's Market Share

Silence Therapeutics Plc Share Performance +137.24% This Year

Silence Therapeutics Plc Profile Silence Therapeutics Plc is a biomedical company that specializes in the discovery, development, and commercialization of innovative RNA-based therapeutics. They employ a business model focused on leveraging their proprietary technology to develop a pipeline of therapeutics targeting various diseases with high unmet medical needs. Through strategic partnerships and licensing agreements, they aim to deliver transformative RNA-based treatments to patients globally. More about Silence Therapeutics Plc's Market Share

Sources: Dicerna Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 8, 2026 1:25 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dicerna Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.